The emergence of bispecific antibodies as novel cancer therapeutics
OA Version
Citation
Abstract
Bispecific antibodies have recently taken the immune-oncology field by storm through its multi-targeting capabilities and unique mechanisms of action. In the past few decades, this therapeutic format has seen an exponential rise, and with every year, new variations of the basic bispecific concept emerge to precipitate new effects. These effects include cell-to-cell binding, enhanced agonism or antagonism, and target internalization. One of the most promising applications for bispecific antibodies is as a bispecific T-cell engager, which can induce inflammatory responses in previously immune-excluded tumors. This paper aims to provide a high-level overview of the functionality, formats, and clinical results of bispecific antibodies and place them in the context of current treatments for cancer.